Press release
Strategic Manufacturing Award: Werum’s PAS-X is part of prize-winning IT program of Rottapharm | Madaus
Production in Dublin, Source Rottapharm | Madaus
Award honors Continuous Improvement Program of pharmaceutical manufacturer / with Werum’s PAS-X Manufacturing IT Business Platform to paperless factory
Lueneburg, Germany, 19 December 2012 – The pharmaceutical company Rottapharm | Madaus has won the 2012 Strategic Manufacturing Award in the category “Outstanding Achievement in Continuous Improvement” and the cross-competition “SMA e-F@ctory Hall of Fame” award for its Irish production plant in Dublin. The prizes pay tribute to the Continuous Improvement Program of Rottapharm | Madaus, in which the PAS-X Manufacturing IT Business Platform of Werum plays an important role.
Werum had rolled out PAS-X step by step at the Dublin plant since 2009. It began with the warehouse implementation, followed by the manufacturing and packaging areas. PAS-X integrates Enterprise Resource Planning (ERP) and several Distributed Control Systems (DCS).
“Our goal is to achieve a paperless factory. For this purpose, we automated the processes in the warehouse, in our manufacturing and packaging areas and reduced the number of manual entries,” said Áine Tobin, Project Manager, Rottapharm | Madaus Ltd. “With PAS-X we were able to eliminate over 720,000 wet signatures and to release batches in less than half the original time. On the other hand, the inventory accuracy has now increased to 99 percent.”
Werum’s PAS-X is a major building block within Rottapharm's Continuous Improvement Program with which the pharmaceutical manufacturer continually reduces non-value-added activities and lastingly expands its competitiveness.
About Rottapharm | Madaus Ltd.
Rottapharm | Madaus is a multinational pharmaceutical group based in Italy with its headquarters and research centre in Monza and possessing branches in over 85 countries. Rottapharm‘s long history of success began in 1961 with the creation of a small laboratory of independent research. From then on, the company has always invested in research, innovation, development and distribution on a global scale of new products mainly in the field of pharmaceuticals and, in the following years, also in the fields of parapharmaceuticals and neutraceuticals. www.rottapharm-madaus.com
About Werum Software & Systems AG
With over 40 years of software development experience, Werum Software & Systems AG is known worldwide for partnering with its global customers to create state-of-the-art software products and solutions. Werum is the internationally leading supplier of Manufacturing IT / Manufacturing Execution Systems for the pharmaceutical and biopharmaceutical industries. Its Manufacturing IT Business Platform PAS-X is used by 16 of the world’s top 30 pharmaceutical and biotech companies in more than 600 installations. Founded in 1969, the IT company employs about 470 people at its headquarters in Lueneburg, Germany, and at eight other locations in Germany, France, the United States, Japan, and Singapore. For more information take a look at our websites at www.werum.com and www.pas-x.com.
Dirk Ebbecke
DirectorCorporate Communications
Werum Software & Systems AG
Wulf-Werum-Strasse 3
21337 Lueneburg, Germany
Tel. +49 4131 8900-689
Fax +49 4131 8900-20
dirk.ebbecke@werum.com
For further information, visit Werum’s press center at www.press.werum.com.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Strategic Manufacturing Award: Werum’s PAS-X is part of prize-winning IT program of Rottapharm | Madaus here
News-ID: 246950 • Views: …
More Releases from Werum Software & Systems AG
Research Made Easy
With their web-based data management system DSHIP the German-based company Werum Software & Systems supports maritime research on board of research vessels all over the world.
The Instagram profile of the current climate research expedition MOSAiC in the North Polar Sea shows straightaway: research work on the high seas may be really fascinating, but it also is extremely laborious, fragmented and highly complex. As they depend on the various environmental conditions…
Werum’s "PAS-X Reports & Labels" Content Packages significantly reduce MES imp …
Werum’s "PAS-X Reports & Labels" Content Packages significantly reduce MES implementation times
Best practice consulting services and “Out of the Box”-templates for GMP-compliant reports and labels
Lueneburg, Germany, 29 January 2014 – By providing "PAS-X Reports & Labels" Content Packages, Werum Software & Systems now offers an even broader range of pre-configured reports and labels along with the associated comprehensive consulting services to its customers.
These packages are based on best practices…
Werum accelerates MBR creation by providing "PAS-X MBR Design Elements" Content …
Werum accelerates MBR creation by providing "PAS-X MBR Design Elements" Content Packages
New "PAS-X MBR Design Elements" Content Packages based on industry best practice / process-specific and fast MBR creation for pharmaceutical production
Lueneburg, Germany, 28 November 2013 – In order for pharma and biotech customers to implement PAS-X MES projects even faster and more easily, Werum Software & Systems expands its PAS-X Content Packages offering further: New on the market are…
Werum equips research vessel Mya II of Alfred Wegener Institute with DSHIP softw …
Werum equips research vessel Mya II of Alfred Wegener Institute with DSHIP software
AWI puts new RV Mya II into service / Werum's data management system DSHIP ensures acquisition, archiving and evaluation of measurement data
Lueneburg, Germany, 23 October 2013 – The new RV Mya II, which has only recently been delivered to the German Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research (AWI), has been equipped by Werum Software…
More Releases for Rottapharm
Hyperuricemia Therapeutic Market Personalized Medicine Is Shaping the Future Sec …
The Global Hyperuricemia Therapeutic Market is estimated to be valued at USD 2.2 billion in 2024 and is expected to reach USD 3.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.Latest Report, titled ""Hyperuricemia Therapeutic Market"" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by C
CoherentMI offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The…
Herbal Medicines Market Is in Huge Demand: Tsumura, Rottapharm Madaus GmbH, Wele …
Advance Market Analytics added research publication document on Worldwide Herbal Medicines Market breaking major business segments and highlighting wider level geographies to get deep dive analysis on market data. The study is a perfect balance bridging both qualitative and quantitative information of Worldwide Herbal Medicines market. The study provides valuable market size data for historical (Volume** & Value) from 2018 to 2023 which is estimated and forecasted till 2028*. Some…
Irritable Bowel Syndrome (IBS) Market Poised for Phenomenal Expansion During the …
The Irritable Bowel Syndrome Market size in the 7MM was approximately USD 1,800 million in 2022, and it is projected to increase during the forecast period. As per DelveInsight, the Irritable Bowel Syndrome Market is anticipated to evolve immensely in the coming years owing to the rise in the geriatric population, the increase in the prevalence of gastrointestinal diseases and disorders, unhealthy diets, and the expected commercial success of upcoming…
Obsessive-Compulsive Disorder Treatment Market To Grow Extensively At Unstoppabl …
A recent market research report added to repository of MR Accuracy Reports is an in-depth analysis of global Obsessive-Compulsive Disorder Treatment. On the basis of historic growth analysis and current scenario of Obsessive-Compulsive Disorder Treatment place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent…
Cholecystokinin Receptor (CCK) Antagonist Market 2020 New Innovations in Medical …
Cholecystokinin Receptor (CCK) Antagonist -Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Cholecystokinin Receptor (CCK) Antagonist Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of…
Diacerein Market potential growth, share, demand and analysis of key players - r …
This detailed market study covers diacerein market growth potentials which can assist the stake holders to understand key trends and prospects in diacerein market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The analysis also…
